Big Cypress Acquisition stockholders voted yesterday in favor of the proposed business combination with SAB Biotherapeutics, a clinical-stage biopharmaceutical company, the SPAC announced.
Approximately 98.3% of the votes cast, representing 78.6% of Big Cypress’ outstanding shares, were in support of the business combination.
No word on redemptions, if any, although Big Cypress shares traded consistently above $10 throughout the redemption period and popped Monday ar $10.47.
SAB is developing a novel immunotherapy platform producing targeted, high potency, fully-human polyclonal antibody therapeutics and advancing programs in infectious disease and immune system disorders.
The transaction is expected to close tomorrow.
Upon closing, the SAB Biotherapeutics common stock and warrants will list on the Nasdaq under SABS and SABSW starting Oct. 25. Read more.
